<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2023.1261261</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Mobilization of the <italic>bla</italic><sub>KPC-14</sub> gene among heterogenous plasmids in extensively drug-resistant hypervirulent <italic>Klebsiella pneumoniae</italic></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wang</surname>
<given-names>Lin</given-names>
</name>
<xref ref-type="author-notes" rid="fn0004"><sup>&#x2020;</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology"/>
<role content-type="https://credit.niso.org/contributor-roles/resources"/>
<role content-type="https://credit.niso.org/contributor-roles/validation"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Shen</surname>
<given-names>Weiyi</given-names>
</name>
<xref ref-type="author-notes" rid="fn0004"><sup>&#x2020;</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation"/>
<role content-type="https://credit.niso.org/contributor-roles/validation"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft"/>
<role content-type="https://credit.niso.org/contributor-roles/software"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cai</surname>
<given-names>Jiachang</given-names>
</name>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1112620/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing"/>
</contrib>
</contrib-group>
<aff><institution>Clinical Microbiology Laboratory, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0005">
<p>Edited by: Benjamin Andrew Evans, University of East Anglia, United Kingdom</p>
</fn>
<fn fn-type="edited-by" id="fn0006">
<p>Reviewed by: Fupin Hu, Fudan University, China; Shangshang Qin, Zhengzhou University, China</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Jiachang Cai, <email>caijiachang@zju.edu.cn</email></corresp>
<fn fn-type="equal" id="fn0004"><p><sup>&#x2020;</sup>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>11</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1261261</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>11</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 Wang, Shen and Cai.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Wang, Shen and Cai</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>Ceftazidime/avibactam (CZA) is an effective alternative for the treatment of infections caused by KPC-producing carbapenem-resistant <italic>Klebsiella pneumoniae</italic> (CRKP). However, KPC variants with CZA resistance have been observed in clinical isolates, further limiting the treatment options of clinical use.</p>
</sec>
<sec>
<title>Methods</title>
<p>In this study, we isolated three KPC-14-producing CRKP from two patients in intensive care units without CZA therapy. The antimicrobial susceptibility was determined using the broth microdilution method. Three CRKP were subjected to whole-genome sequencing to analyze the phylogenetic relatedness and the carriage of antimicrobial resistance genes and virulence factors. Long-read sequencing was also performed to obtain the complete sequences of the plasmids. The horizontal transfer of the <italic>bla</italic><sub>KPC-14</sub> gene was evaluated by conjugation experiments.</p>
</sec>
<sec>
<title>Results</title>
<p>Three CRKP displayed resistance or reduced susceptibility to ceftazidime/avibactam, colistin, and tigecycline. Single-nucleotide polymorphism (SNP) analysis demonstrated the close phylogenetic distance between these strains. A highly similar IncFII/IncR plasmid encoding <italic>bla</italic><sub>KPC-14</sub> was shared by three CRKP, with <italic>bla</italic><sub>KPC-14</sub> located in an NTE<sub>KPC</sub>-Ib element with the core region of IS<italic>Kpn27</italic>- <italic>bla</italic><sub>KPC-14</sub>-IS<italic>Kpn6</italic>. This structure containing <italic>bla</italic><sub>KPC-14</sub> was also observed in another <italic>tet</italic>(A)-carrying plasmid that belonged to an unknown Inc-type in two out of three isolates. The horizontal transferability of these integrated plasmids to Escherichia coli EC600 was confirmed by the cotransmission of <italic>tet</italic>(A) and <italic>bla</italic><sub>KPC-14</sub> genes, but the single transfer of <italic>bla</italic><sub>KPC-14</sub> on the IncFII/IncR plasmid failed. Three CRKP expressed yersiniabactin and carried a hypervirulence plasmid encoding <italic>rmpA2</italic> and aerobactin-related genes, and were thus classified as carbapenem-resistant hypervirulent <italic>K. pneumoniae</italic> (hvKP).</p>
</sec>
<sec>
<title>Discussion</title>
<p>In this study, we reported the evolution of a mosaic plasmid encoding the <italic>bla</italic><sub>KPC-14</sub> gene via mobile elements in extensively drug-resistant hvKP. The <italic>bla</italic><sub>KPC-14</sub> gene is prone to integrate into other conjugative plasmids via the NTE<sub>KPC</sub>-Ib element, further facilitating the spread of ceftazidime/avibactam resistance.</p>
</sec>
</abstract>
<kwd-group>
<kwd><italic>bla</italic><sub>KPC-14</sub> gene</kwd>
<kwd>ceftazidime/avibactam</kwd>
<kwd>CR-hvKp</kwd>
<kwd><italic>Klebsiella pneumoniae</italic></kwd>
<kwd>gene transfer</kwd>
</kwd-group>
<contract-num rid="cn1">LY22H200001</contract-num>
<contract-sponsor id="cn1">Zhejiang Provincial Natural Science Foundation of China</contract-sponsor>
<counts>
<fig-count count="3"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="39"/>
<page-count count="9"/>
<word-count count="6436"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Antimicrobials, Resistance and Chemotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1.</label>
<title>Introduction</title>
<p>The widespread of carbapenem-resistant <italic>Klebsiella pneumoniae</italic> (CRKP) is considered an urgent threat to public health, as it complicates patient care and increases morbidity and mortality in cases of infection (<xref ref-type="bibr" rid="ref35">Wang M. et al., 2022</xref>; <xref ref-type="bibr" rid="ref31">P&#x00E9;rez-Galera et al., 2023</xref>). Available data from the China Antimicrobial Surveillance Network (CHINET<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref>) showed that the prevalence of CRKP has rapidly increased in China, from 2.9% in 2005 to 24.2% in 2022. Colistin and tigecycline constitute some of the last resorts for the treatment of CRKP infections, however, resistance to these antibiotics in CRKP strains has also been reported recently, further reducing the repertoire of useful antibiotics (<xref ref-type="bibr" rid="ref8">Chen et al., 2021</xref>; <xref ref-type="bibr" rid="ref32">Tian et al., 2021</xref>).</p>
<p>Ceftazidime/avibactam (CZA), a novel &#x03B2;-lactam/&#x03B2;-lactamase inhibitor combination, is an effective alternative for the treatment of CRKP infections (<xref ref-type="bibr" rid="ref33">Van Duin and Bonomo, 2016</xref>). This combination shields ceftazidime from breakdown by Ambler class A, class C, and some class D &#x03B2;-lactamases and thus exhibits potent inhibition of strains producing KPC and OXA-48-like carbapenemases (<xref ref-type="bibr" rid="ref13">Criscuolo and Trecarichi, 2020</xref>). KPC-producing CRKP is widespread globally and is the predominant type of CRKP in China, which is frequently related to nosocomial outbreaks (<xref ref-type="bibr" rid="ref16">Findlay et al., 2021</xref>; <xref ref-type="bibr" rid="ref35">Wang L. et al., 2022</xref>; <xref ref-type="bibr" rid="ref36">Wang M. et al., 2022</xref>). Although recent studies have shown evidence for CZA as a promising option for such infections, resistance to this antibiotic has rapidly evolved, mainly due to the production of variants of KPC-2 or KPC-3 enzymes (<xref ref-type="bibr" rid="ref18">Humphries and Hemarajata, 2017</xref>; <xref ref-type="bibr" rid="ref15">El-Kady et al., 2022</xref>). The single amino acid substitution that confers CZA resistance was commonly encountered in the omega loop (positions 164&#x2013;179), particularly for the Asp179Tyr (D179Y) mutation in KPC-3 (KPC-31) and KPC-2 (KPC-33) (<xref ref-type="bibr" rid="ref26">Livermore et al., 2015</xref>; <xref ref-type="bibr" rid="ref2">Barnes et al., 2017</xref>). Additionally, KPC variants with CZA-resistance mediated by amino acid changes outside the omega loop region (e.g., KPC-41, KPC-23, KPC-14, KPC-8, KPC-123, and KPC-93) were also observed in the clinical isolates from patients following CZA therapy and those who were not treated with CZA (<xref ref-type="bibr" rid="ref3">Bianco et al., 2021</xref>; <xref ref-type="bibr" rid="ref25">Liu et al., 2022b</xref>; <xref ref-type="bibr" rid="ref36">Wang L. et al., 2022</xref>). KPC-14, the variant with a deletion of two amino acids (&#x0394;242-GT-243) of KPC-2 that exhibits CZA resistance, has been sporadically detected in clinical isolates of CRKP (<xref ref-type="bibr" rid="ref4">Bianco et al., 2020</xref>; <xref ref-type="bibr" rid="ref29">Niu et al., 2020</xref>; <xref ref-type="bibr" rid="ref23">Linh et al., 2021</xref>; <xref ref-type="bibr" rid="ref19">Jiang et al., 2022</xref>).</p>
<p>Here, we investigated the genetic relationship of CRKP harboring two structurally distinct <italic>bla</italic><sub>KPC-14</sub>-encoding plasmids and analyzed the evolution of one plasmid that was able to undergo horizontal transfer between <italic>Enterobacterales</italic>.</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<label>2.</label>
<title>Materials and methods</title>
<sec id="sec3">
<label>2.1.</label>
<title>Patients and bacterial strains</title>
<p>Three CRKP (strains SP1023 and F1025 from Patient A, and strain SP1030 from Patient B) were isolated from two patients admitted to the neurology intensive care unit (NICU) of a tertiary hospital in Hangzhou City in 2022. Species identification was determined by MALDI-TOF MS (Bruker Daltonik GmbH, Bremen, Germany). This study was approved by the Ethics Committee of The Second Affiliated Hospital of Zhejiang University School of Medicine.</p>
<p>Patient A, a 38-year-old male, had poorly controlled hypertension for several years. He underwent three consecutive intracranial hematoma evacuations at a local hospital due to cerebellar hemorrhage. Blood cultures revealed carbapenem-resistant <italic>Acinetobacter baumannii</italic> (CRAB) and a combination of cefoperazone/sulbactam (1,1, 2&#x2009;g IV every 6&#x2009;h) and polymyxin B (750,000&#x2009;IU IV every 12&#x2009;h) was administered (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The patient was in a coma and was transferred to the NICU of our hospital for further treatment. Upon admission, the patient received supportive treatments, including mechanical ventilation, blood transfusion, fluid replacement, and appropriate medications. The original antimicrobial therapy regimen was continued. The subsequent sputum culture revealed the growth of <italic>Klebsiella aerogenes</italic> and cefoperazone/sulbactam- and carbapenem-resistant <italic>A. baumannii</italic>. Therefore, cefoperazone/sulbactam was replaced with tigecycline (100&#x2009;mg IV every 12&#x2009;h) on Day 7. Nine days later (Day 16), both organisms were cleared. However, CRKP (strain SP1023) exhibiting ceftazidime/avibactam and polymyxin B resistance was isolated from the sputum sample (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). On Day 18, fecal screening for CRE yielded pandrug-resistant <italic>K. pneumoniae</italic> (strain F1025), which was resistant to ceftazidime/avibactam, polymyxin B, and tigecycline (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In addition to CRKP, <italic>Pseudomonas aeruginosa</italic> and carbapenem-resistant <italic>A. baumannii</italic> (CRAB) were detected in the sputum sample on Day 32. Meropenem was used (1&#x2009;g IV every 12&#x2009;h) instead of the previous antimicrobials, and only CRKP was cleared after 9 days of treatment. Tigecycline was used again, and amikacin (400&#x2009;mg nasogastric feeding every 12&#x2009;h) was added to the treatment regimen 5 days later. However, <italic>P. aeruginosa</italic> that developed carbapenem resistance and CRAB persisted in the patient&#x2019;s respiratory tract. Due to his extremely poor condition and acute exacerbation of chronic renal failure, the patient died of multiple organ failure on Day 68.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Antimicrobial treatments and bacterial isolation of Patient A <bold>(A)</bold> and Patient B <bold>(B)</bold>. CRAB, carbapenem-resistant <italic>Acinetobacter baumannii</italic>; KA, <italic>Klebsiella aerogenes</italic>; ARKP, ceftazidime/avibactam-resistant <italic>Klebsiella pneumoniae</italic>; CSPA, carbapenem-susceptible <italic>Pseudomonas aeruginosa</italic>; CRPA, carbapenem-resistant <italic>Pseudomonas aeruginosa</italic>; CRKP, carbapenem-resistant <italic>Klebsiella pneumoniae</italic> (ceftazidime/avibactam-susceptible); SM, <italic>Stenotrophomonas maltophilia</italic>; SCF, cefoperazone/sulbactam; PB, polymyxin B; TGC, tigecycline; MEM, meropenem; AK, amikacin; TZP, piperacillin/tazobactam.</p>
</caption>
<graphic xlink:href="fmicb-14-1261261-g001.tif"/>
</fig>
<p>Patient B, a 40-year-old male with spontaneous intracerebral hemorrhage, underwent surgical evacuation of the intracranial hematoma at a local hospital. Six days later, he remained in a coma and was transferred to the NICU of our hospital. The CT scans showed postoperative hematoma in the surgical area and scattered infiltrates in both lungs. The patient received supportive treatments to reduce intracranial pressure, sedation, pain management, enteral nutrition, endotracheal intubation, and mechanical ventilation. Additionally, piperacillin/tazobactam (8:1, 4.5&#x2009;g IV every 6&#x2009;h) was administered for antimicrobial therapy throughout the hospitalization period (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). On the second day of admission, CRAB was isolated from the sputum sample and persisted until discharge. On Day 17 and Day 19, CRKP (strain SP1030) was detected in the sputum culture that was resistant to ceftazidime/avibactam and colistin (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). After 8 days of mechanical ventilation, the patient was weaned off the ventilator (Day 15). Since the patient&#x2019;s vital signs stabilized and his mental function recovered, he was discharged for further treatment at a rehabilitation hospital on Day 20.</p>
</sec>
<sec id="sec4">
<label>2.2.</label>
<title>Antimicrobial susceptibility tests</title>
<p>The minimal inhibitory concentrations (MICs) of 18 antimicrobial agents, including imipenem, meropenem, ertapenem, ceftazidime/avibactam, ceftazidime, cefotaxime, cefepime, piperacillin/tazobactam, cefoperazone/sulbactam, cefmetazole, aztreonam, ciprofloxacin, amikacin, chloramphenicol, fosfomycin, tetracycline, tigecycline, and colistin, were determined using the broth microdilution method (<xref ref-type="bibr" rid="ref10">Clinical and Laboratory Standards Institute, 2018</xref>) and interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (<xref ref-type="bibr" rid="ref11">Clinical and Laboratory Standards Institute, 2021</xref>). Tigecycline susceptibility was interpreted using breakpoints recommended by the US Food and Drug Administration.<xref ref-type="fn" rid="fn0002"><sup>2</sup></xref> <italic>Escherichia coli</italic> ATCC 25922, <italic>K. pneumoniae</italic> 700603, and <italic>Pseudomonas aeruginosa</italic> ATCC 27583 were used as the quality control strains in parallel.</p>
</sec>
<sec id="sec5">
<label>2.3.</label>
<title>Whole genome sequencing and genome analysis</title>
<p>To investigate the evolution and genetic relatedness of these CRKP, the genomic DNA of three CRKP (strains SP1023, F1025, and SP1030) was subjected to WGS by both the short-read Illumina NovaSeq 6000 platform and the hybrid long-read Oxford Nanopore PromethION 48 platform. The complete genome was assembled by Flye assembler v2.9.2 (<xref ref-type="bibr" rid="ref20">Kolmogorov et al., 2020</xref>) and polished by Pilon v1.24 (<xref ref-type="bibr" rid="ref34">Walker et al., 2014</xref>). The antimicrobial resistance genes and the plasmid types for the assembly scaffolds were identified by ResFinder 4.1 and PlasmidFinder 2.0, respectively, at the Center for Genomic Epidemiology.<xref ref-type="fn" rid="fn0003"><sup>3</sup></xref> The sequence types and virulence factors were identified using Kleborate v0.3.0 (<xref ref-type="bibr" rid="ref21">Lam et al., 2021</xref>). A pairwise comparison of genomes and variant callings for single-nucleotide polymorphisms (SNPs) was conducted using Snippy v4.4.5 with default settings. The plasmids encoding <italic>bla</italic><sub>KPC-14</sub> and virulence-associated genes were annotated by the RAST server (<xref ref-type="bibr" rid="ref30">Overbeek et al., 2014</xref>) and BLASTN program. The comparison of plasmids was visualized and annotated by BRIG v0.95 (<xref ref-type="bibr" rid="ref1">Alikhan et al., 2011</xref>).</p>
</sec>
<sec id="sec6">
<label>2.4.</label>
<title>Conjugation experiment</title>
<p>The transferability of <italic>bla</italic><sub>KPC-14</sub> genes was estimated by conjugation experiments with filter mating methods (<xref ref-type="bibr" rid="ref5">Cai et al., 2008</xref>). Rifampin-resistant <italic>E. coli</italic> EC600 was used as the recipient strain. The putative transconjugants grown on selective media supplemented with 8&#x2009;mg/L CZA or 30&#x2009;mg/L tetracycline were identified by MALDI-TOF MS and screened for the presence of <italic>bla</italic><sub>KPC-14</sub> genes. The conjugation frequency equaled the number of transconjugants divided by the number of recipients.</p>
</sec>
<sec id="sec7">
<label>2.5.</label>
<title>Virulence testing in the <italic>Galleria mellonella</italic> infection model</title>
<p>The <italic>G. mellonella</italic> (wax moth larvae) infection model was used to confirm the hypervirulent phenotype of the CRKP strains as previously described (<xref ref-type="bibr" rid="ref28">McLaughlin et al., 2014</xref>). Overnight cultures of <italic>K. pneumoniae</italic> were diluted in sterile phosphate-buffered saline to obtain a concentration of 10<sup>8</sup>&#x2009;CFU/mL. Wax moth larvae weighing 250&#x2013;300&#x2009;mg (Tianjin Huiyude Biotech Company, Tianjin, China) were injected with 10&#x2009;&#x03BC;L bacterial suspension and incubated for 48&#x2009;h at 35&#x00B0;C. The survival rate of <italic>G. mellonella</italic> was recorded at 12&#x2009;h, 24&#x2009;h, 36&#x2009;h, and 48&#x2009;h. ST11 <italic>K. pneumoniae</italic> FJ8 without virulence factors and the hypervirulent <italic>K. pneumoniae</italic> 4 were used as the negative and positive controls, respectively (<xref ref-type="bibr" rid="ref17">Gu et al., 2018</xref>). All experiments were performed in triplicate. Kaplan&#x2013;Meier survival curves were plotted using Prism 9.</p>
</sec>
<sec id="sec8">
<label>2.6.</label>
<title>Nucleotide sequence accession numbers</title>
<p>The complete genome of the chromosome and plasmids for <italic>K. pneumoniae</italic> SP1023, F1025, and SP1030 were downloaded with BioSample accession numbers SAMN36464959, SAMN36465167, and SAMN36465169, respectively.</p>
</sec>
</sec>
<sec sec-type="results" id="sec9">
<label>3.</label>
<title>Results</title>
<sec id="sec10">
<label>3.1.</label>
<title>Antimicrobial susceptibility results</title>
<p>As <xref ref-type="table" rid="tab1">Table 1</xref> illustrated, three CRKP shared a high-level resistance to CZA with MIC values of &#x003E;64/4&#x2009;mg/L and showed resistance or decreased susceptibility to meropenem and ertapenem. These strains also shared an extensive drug resistance (XDR) profile (<xref ref-type="bibr" rid="ref27">Magiorakos et al., 2012</xref>) to ceftazidime, cefotaxime, cefepime, aztreonam, ciprofloxacin, amikacin, chloramphenicol, fosfomycin, and tetracycline but retained susceptibility to imipenem. More worrisome, resistance to colistin was observed in these CRKP, and <italic>K. pneumoniae</italic> F1024 exhibited additional resistance to another clinically important antibiotic, tigecycline, which was interpreted as resistance to almost all the antimicrobial agents frequently used in clinical settings.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Antimicrobial susceptibility results of <italic>K. pneumoniae</italic> isolates and their <italic>E. coli</italic> transconjugants.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" rowspan="2">Strain</th>
<th align="center" valign="top" colspan="18">MICs (mg/L)</th>
</tr>
<tr>
<th align="center" valign="top">IPM<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></th>
<th align="center" valign="top">MEM</th>
<th align="center" valign="top">ETP</th>
<th align="center" valign="top">CZA</th>
<th align="center" valign="top">CAZ</th>
<th align="center" valign="top">CTX</th>
<th align="center" valign="top">FEP</th>
<th align="center" valign="top">TZP</th>
<th align="center" valign="top">SCF</th>
<th align="center" valign="top">CMZ</th>
<th align="center" valign="top">ATM</th>
<th align="center" valign="top">CIP</th>
<th align="center" valign="top">AK</th>
<th align="center" valign="top">CHL</th>
<th align="center" valign="top">FOS</th>
<th align="center" valign="top">TE</th>
<th align="center" valign="top">TGC</th>
<th align="center" valign="top">COL</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top"><italic>K. pneumoniae</italic> SP1023</td>
<td align="center" valign="top">0.25</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">&#x003E;64/4</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">64</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">32/4</td>
<td align="center" valign="top">32/16</td>
<td align="center" valign="top">32</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;32</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;256</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top"><italic>K. pneumoniae</italic> F1025</td>
<td align="center" valign="top">0.5</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">16</td>
<td align="center" valign="top">&#x003E;64/4</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">&#x003E;256/4</td>
<td align="center" valign="top">64/32</td>
<td align="center" valign="top">128</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;32</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;256</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top"><italic>K. pneumoniae</italic> SP1030</td>
<td align="center" valign="top">0.5</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">&#x003E;64/4</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">&#x003E;256/4</td>
<td align="center" valign="top">128/64</td>
<td align="center" valign="top">32</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;32</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">&#x003E;256</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top">Transconjugant SP1023-TE<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="center" valign="top">0.25</td>
<td align="center" valign="top">0.06</td>
<td align="center" valign="top">&#x2264;0.03</td>
<td align="center" valign="top">&#x2264;0.5/4</td>
<td align="center" valign="top">&#x2264;0.5</td>
<td align="center" valign="top">&#x2264;0.5</td>
<td align="center" valign="top">&#x2264;0.5</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;2</td>
<td align="center" valign="top">&#x2264;1</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">&#x2264;4</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">&#x2264;8</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">0.125</td>
<td align="center" valign="top">&#x2264;0.5</td>
</tr>
<tr>
<td align="left" valign="top">Transconjugant F1025-CZA</td>
<td align="center" valign="top">0.25</td>
<td align="center" valign="top">0.06</td>
<td align="center" valign="top">0.25</td>
<td align="center" valign="top">16/4</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">32</td>
<td align="center" valign="top">16</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;2</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">&#x2264;4</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">&#x2264;8</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">0.125</td>
<td align="center" valign="top">&#x2264;0.5</td>
</tr>
<tr>
<td align="left" valign="top">Transconjugant F1025-TE</td>
<td align="center" valign="top">0.25</td>
<td align="center" valign="top">0.06</td>
<td align="center" valign="top">0.25</td>
<td align="center" valign="top">16/4</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">32</td>
<td align="center" valign="top">16</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;2</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">&#x2264;4</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">&#x2264;8</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">0.125</td>
<td align="center" valign="top">&#x2264;0.5</td>
</tr>
<tr>
<td align="left" valign="top">Transconjugant SP1030-CZA</td>
<td align="center" valign="top">0.25</td>
<td align="center" valign="top">0.06</td>
<td align="center" valign="top">0.5</td>
<td align="center" valign="top">16/4</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">32</td>
<td align="center" valign="top">32</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;2</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">&#x2264;4</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">&#x2264;8</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">0.125</td>
<td align="center" valign="top">&#x2264;0.5</td>
</tr>
<tr>
<td align="left" valign="top">Transconjugant SP1030-TE</td>
<td align="center" valign="top">0.25</td>
<td align="center" valign="top">0.06</td>
<td align="center" valign="top">0.5</td>
<td align="center" valign="top">16/4</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">32</td>
<td align="center" valign="top">32</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;2</td>
<td align="center" valign="top">&#x003E;128</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">&#x2264;4</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">&#x2264;8</td>
<td align="center" valign="top">&#x003E;64</td>
<td align="center" valign="top">0.125</td>
<td align="center" valign="top">&#x2264;0.5</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. coli</italic> EC600</td>
<td align="center" valign="top">0.25</td>
<td align="center" valign="top">0.06</td>
<td align="center" valign="top">&#x2264;0.03</td>
<td align="center" valign="top">&#x2264;0.5/4</td>
<td align="center" valign="top">&#x2264;0.5</td>
<td align="center" valign="top">&#x2264;0.5</td>
<td align="center" valign="top">&#x2264;0.5</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;8/4</td>
<td align="center" valign="top">&#x2264;2</td>
<td align="center" valign="top">&#x2264;1</td>
<td align="center" valign="top">&#x2264;0.25</td>
<td align="center" valign="top">&#x2264;4</td>
<td align="center" valign="top">&#x2264;4</td>
<td align="center" valign="top">&#x2264;8</td>
<td align="center" valign="top">&#x2264;1</td>
<td align="center" valign="top">0.06</td>
<td align="center" valign="top">1</td>
</tr>
</tbody>
</table>
<table-wrap-foot><fn id="tfn1">
<label>a</label>
<p><italic>E. coli</italic> transconjugants were selected by two different agar plates containing ceftazidime/avibactam or tetracycline, respectively.</p>
</fn><fn id="tfn2">
<label>b</label>
<p>IPM, imipenem; MEM, meropenem; ETP, ertapenem; CZA, ceftazidime/avibactam; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; TZP, piperacillin/tazobactam; SCF, cefoperazone/sulbactam; CMZ, cefmetazole; ATM, aztreonam; CIP, ciprofloxacin; AK, amikacin; CHL, chloramphenicol; FOS, fosfomycin; TE, tetracycline; TGC, tigecycline; COL, colistin.</p>
</fn> <p>For piperacillin/tazobactam and ceftazidime/avibactam, the tazobactam and avibactam were tested at a fixed concentration of 4&#x2009;mg/L. For cefoperazone/sulbactam, the combination was tested with concentrations of 2:1 ratio (antibiotic: inhibitor).</p></table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec11">
<label>3.2.</label>
<title>Whole genome analysis of KPC-14-producing isolates</title>
<p>All three CRKP were identified as the ST11 type, which was the predominant ST type of CRKP in China (<xref ref-type="bibr" rid="ref24">Liu et al., 2022a</xref>). Moreover, these three strains all belonged to the K64 serotype. Genome-based phylogenetic analysis suggested that these CRKP were closely related within 27 SNPs (with strain F1025 as the reference genome), indicating that these XDR strains originated from the same clone.</p>
<p>Whole-genome analysis demonstrated that three CRKP exhibited a similar carriage profile of &#x03B2;-lactamase genes, including <italic>bla</italic><sub>KPC-14</sub>, <italic>bla</italic><sub>SHV-11</sub>, <italic>bla</italic><sub>TEM-1</sub>, and <italic>bla</italic><sub>LAP-2</sub>, while <italic>K. pneumoniae</italic> F1025 and SP1030 additionally expressed SHV-12 (<xref ref-type="table" rid="tab2">Table 2</xref>). However, the amplification of the <italic>bla</italic><sub>KPC</sub> gene failed both in <italic>A.baumannii</italic> and <italic>P. aeruginosa</italic> isolated from Patient A. Multiple antimicrobial resistance genes were also identified in three CRKP, conferring resistance to quinolones (<italic>qnrS1</italic>), phenicols (<italic>catA2</italic>), sulfonamides (<italic>sul1</italic> and <italic>sul2</italic>), tetracyclines [<italic>tet</italic>(A)], fosfomycin (<italic>fosA</italic> and <italic>fosA3</italic>), and aminoglycosides (<italic>aadA2b</italic> and <italic>rmtB</italic>). Detailed analysis showed three CRKP shared that mutations for type 1 Tet(A) variants (I5R, V55M, I75V, T84A, S201A, F202S, and V203F) and the insertion of IS<italic>Kpn26</italic> elements at position 75 in the <italic>acrR</italic> gene, both of which contributed to the elevated MICs of tigecycline (<xref ref-type="bibr" rid="ref9">Chiu et al., 2017</xref>). Insertional inactivation by IS<italic>Kpn18</italic> was also detected in <italic>ramR</italic>, another tigecycline resistance determinant gene, further driving the generation of resistance to this antibiotic in <italic>K. pneumoniae</italic> SP1025. The <italic>mgrB</italic> genes was interrupted by IS<italic>Kpn26</italic> at the same position (nucleotide 75) in three CRKP, thus accounting for the resistance to colistin.</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Clinical and genetic characteristics of three KPC-14-producing <italic>K. pneumoniae</italic> isolates.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Strain</th>
<th align="left" valign="middle">Patient</th>
<th align="left" valign="middle">Gender</th>
<th align="left" valign="middle">Age</th>
<th align="left" valign="middle">Diagnosis</th>
<th align="left" valign="middle">Specimen</th>
<th align="left" valign="middle">Antibiotic resistance genes</th>
<th align="left" valign="middle">Virulence factors</th>
<th align="left" valign="middle"><italic>mgrB</italic> mutation</th>
<th align="left" valign="middle"><italic>ramR</italic> mutation</th>
<th align="left" valign="middle"><italic>acrR</italic> mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top"><italic>K. pneumoniae</italic> SP1023</td>
<td align="left" valign="top">Patient A</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">38</td>
<td align="left" valign="top">Cerebral hemorrhage</td>
<td align="left" valign="top">Sputum</td>
<td align="left" valign="top"><italic>bla</italic><sub>KPC-14</sub>, <italic>bla</italic><sub>SHV-11</sub>, <italic>bla</italic><sub>TEM-1</sub>, <italic>bla</italic><sub>LAP-2</sub>, <italic>qnrS1</italic>, <italic>catA2</italic>, <italic>tet</italic>(A), <italic>fosA</italic>, <italic>fosA3</italic>, <italic>sul1</italic>, <italic>sul2</italic>, <italic>aadA2b</italic>, <italic>rmtB</italic></td>
<td align="left" valign="top">RmpA2, aerobactin, yersiniabactin</td>
<td align="left" valign="top">IS<italic>Kpn26</italic> insertion at nt 75</td>
<td align="left" valign="top">Wild type</td>
<td align="left" valign="top">IS<italic>Kpn26</italic> insertion at nt 281</td>
</tr>
<tr>
<td align="left" valign="top"><italic>K. pneumoniae</italic> F1025</td>
<td align="left" valign="top">Patient A</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">38</td>
<td align="left" valign="top">Cerebral hemorrhage</td>
<td align="left" valign="top">Feces</td>
<td align="left" valign="top"><italic>bla</italic><sub>KPC-14</sub>, <italic>bla</italic><sub>SHV-11</sub>, <italic>bla</italic><sub>SHV-12</sub>, <italic>bla</italic><sub>TEM-1</sub>, <italic>bla</italic><sub>LAP-2</sub>, <italic>qnrS1</italic>, <italic>catA2</italic>, <italic>tet</italic>(A), <italic>fosA</italic>, <italic>fosA3</italic>, <italic>sul1</italic>, <italic>sul2</italic>, <italic>aadA2b</italic>, <italic>rmtB</italic></td>
<td align="left" valign="top">RmpA2, aerobactin, yersiniabactin</td>
<td align="left" valign="top">IS<italic>Kpn26</italic> insertion at nt 75</td>
<td align="left" valign="top">IS<italic>Kpn18</italic> insertion at nt 396</td>
<td align="left" valign="top">IS<italic>Kpn26</italic> insertion at nt 281</td>
</tr>
<tr>
<td align="left" valign="top"><italic>K. pneumoniae</italic> SP1030</td>
<td align="left" valign="top">Patient B</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">40</td>
<td align="left" valign="top">Cerebral hemorrhage</td>
<td align="left" valign="top">Sputum</td>
<td align="left" valign="top"><italic>bla</italic><sub>KPC-14</sub>, <italic>bla</italic><sub>SHV-11</sub>, <italic>bla</italic><sub>SHV-12</sub>, <italic>bla</italic><sub>TEM-1</sub>, <italic>bla</italic><sub>LAP-2</sub>, <italic>qnrS1</italic>, <italic>catA2</italic>, <italic>tet</italic>(A), <italic>fosA</italic>, <italic>fosA3</italic>, <italic>sul1</italic>, <italic>sul2</italic>, <italic>aadA2b</italic>, <italic>rmtB</italic></td>
<td align="left" valign="top">RmpA2, aerobactin, yersiniabactin</td>
<td align="left" valign="top">IS<italic>Kpn26</italic> insertion at nt 75</td>
<td align="left" valign="top">Wild type</td>
<td align="left" valign="top">IS<italic>Kpn26</italic> insertion at nt 281</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec12">
<label>3.3.</label>
<title>Transferability of <italic>bla</italic><sup>KPC-14</sup>-carrying plasmids</title>
<p>The <italic>bla</italic><sub>KPC-14</sub> gene could be conjugated into <italic>E. coli</italic> EC600 from <italic>K. pneumoniae</italic> F1025 and SP1030 with similar conjugation efficiencies of 2.1&#x2009;&#x00D7;&#x2009;10<sup>&#x2212;5</sup> and 3.5&#x2009;&#x00D7;&#x2009;10<sup>&#x2212;5</sup>, respectively, but conjugation failed in strain SP1023, suggesting a different location of the <italic>bla</italic><sub>KPC-14</sub> gene among these strains. Elevated CZA and several &#x03B2;-lactam MIC values were observed in <italic>E. coli</italic> transconjugants for <italic>K. pneumoniae</italic> F1025 and SP1030, confirming the functionality of <italic>bla</italic><sub>KPC-14</sub> (<xref ref-type="table" rid="tab1">Table 1</xref>). Notably, these <italic>E. coli</italic> transconjugants also showed resistance to tetracycline and slightly higher tigecycline MIC values, indicating the possible cotransfer of <italic>tet</italic>(A) and <italic>bla</italic><sub>KPC-14</sub> genes. Therefore, selective media containing tetracycline were used to screen for putative transconjugants. Each of the three CRKP was able to transfer the <italic>tet</italic>(A) gene to the recipient <italic>E. coli</italic> EC600 with a similar efficiency at approximately 10<sup>&#x2212;5</sup>; however, <italic>E. coli</italic> transconjugants with different donors displayed heterogeneity in antimicrobial susceptibility profiles. Unlike the <italic>E. coli</italic> transconjugants F1025-TE and SP1030-TE (with <italic>K. pneumoniae</italic> F1025 and SP1030 as donors, respectively), which displayed similar profiles to those of their counterparts for <italic>bla</italic><sub>KPC-14</sub>, the <italic>E. coli</italic> transconjugant SP1023-TE (with <italic>K. pneumoniae</italic> SP1023 as the donor) showed decreased susceptibility to tetracycline and tigecycline but retained the same MIC values for CZA and other &#x03B2;-lactams as the recipient strain. The amplification of <italic>bla</italic><sub>KPC-14</sub> was also carried out in <italic>E. coli</italic> transconjugants F1025-TE and SP1030-TE, but failed in SP1023-TE, further supporting the dissimilar <italic>bla</italic><sub>KPC-14</sub> gene locations and plasmid carriage of the three CRKP.</p>
</sec>
<sec id="sec13">
<label>3.4.</label>
<title>Molecular analysis of <italic>bla</italic><sub>KPC-14</sub>-carrying plasmids</title>
<p>To clarify the location and genetic platforms of <italic>bla</italic><sub>KPC-14</sub> genes, hybrid long-read sequencing of all three strains was performed. This yielded the complete genome for three CRKP with similar sizes of approximately 6 Mbp, consisting of one chromosome and varied numbers of plasmids (<xref ref-type="table" rid="tab3">Table 3</xref>). A similar IncFII/IncR hybrid plasmid encoding <italic>bla</italic><sub>KPC-14</sub> was harbored by all three CRKP, designated as plasmids pSP1023-KPC, pF1025-KPC, and pSP1030-KPC for <italic>K. pneumoniae</italic> SP1023, F1025, and SP1030, respectively. These plasmids carried a variety of additional antimicrobial resistance determinants, including the <italic>bla</italic><sub>TEM-1</sub>, <italic>fosA3</italic>, and <italic>rmtB</italic> genes, with sizes ranging from 112,363&#x2013;112,364&#x2009;bp. Blast analysis demonstrated that the backbone of this plasmid showed the highest similarity to plasmid pCRKP66R-3 with 100% identity (100% coverage, GenBank accession CP063835), which harbored the <italic>bla</italic><sub>KPC-2</sub> gene. These plasmids also displayed 100% identity to two other <italic>bla</italic><sub>KPC-2</sub>-encoding plasmids named plasmid pC76-KPC (86% coverage, GenBank accession CP080299) and pCT77-KPC (87% coverage, GenBank accession CP080305), both of which were previously discovered in CRKP in our hospital (<xref ref-type="fig" rid="fig2">Figure 2</xref>) (<xref ref-type="bibr" rid="ref8">Chen et al., 2021</xref>). The <italic>bla</italic><sub>KPC-14</sub> gene was in the non-Tn<italic>4401</italic> element as an NTE<sub>KPC</sub>-Ib-like transposon with a genetic array of &#x201C;IS<italic>26</italic>-&#x0394;Tn<italic>3</italic>-IS<italic>Kpn8</italic>-<italic>bla</italic><sub>KPC-14</sub>-IS<italic>Kpn6</italic>-<italic>korC-klcA-rep-</italic>orf-IS<italic>26</italic>,&#x201D; which was commonly and uniquely identified in ST11 KPC-producing CRKP (<xref ref-type="bibr" rid="ref38">Yang et al., 2021</xref>). Consistent with many IncFIIK/IncR <italic>bla</italic><sub>KPC</sub>-harboring plasmids widely disseminated in China, this plasmid was nonconjugative, which was probably due to the absence of relaxase, thus explaining the failure of the single transfer of <italic>bla</italic><sub>KPC-14</sub> in the conjugation experiment.</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>Location of antimicrobial resistance genes and virulence genes.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Strain</th>
<th align="left" valign="middle">Patient</th>
<th align="left" valign="middle">Chromosome</th>
<th align="left" valign="middle"><italic>bla</italic><sub>KPC</sub>-carrying plasmid</th>
<th align="left" valign="middle"><italic>tet</italic>(A)-carrying plasmid</th>
<th align="left" valign="middle">Virulence plasmid</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top"><italic>K. pneumoniae</italic> SP1023</td>
<td align="left" valign="top">Patient A</td>
<td align="left" valign="top">4,747,758&#x2009;bp, <italic>bla</italic><sub>SHV-11</sub>, <italic>fosA</italic>, <italic>sul1</italic>, <italic>aadA2b</italic>, <italic>irp1</italic>, <italic>irp2</italic><break/>No. of SNPs: 3<xref ref-type="table-fn" rid="tfn3"><sup>a</sup></xref></td>
<td align="left" valign="top">112,364&#x2009;bp, nonconjugative, <italic>bla</italic><sub>KPC-14</sub>, <italic>bla</italic><sub>TEM-1</sub>, <italic>fosA3</italic>, <italic>rmtB</italic><break/>No. of SNPs: 0</td>
<td align="left" valign="top">84,754&#x2009;bp, conjugative, <italic>tet</italic>(A), <italic>catA2</italic>, <italic>bla</italic><sub>LAP-2</sub>, <italic>qnrS1</italic>, <italic>sul2</italic><break/>No. of SNPs: 1</td>
<td align="left" valign="top">204,778&#x2009;bp, <italic>rmpA2</italic>, <italic>iutA</italic>, <italic>iucABCD</italic><break/>No. of SNPs: 0</td>
</tr>
<tr>
<td align="left" valign="top"><italic>K. pneumoniae</italic> F1025</td>
<td align="left" valign="top">Patient A</td>
<td align="left" valign="top">5,424,169&#x2009;bp, <italic>bla</italic><sub>SHV-11</sub>, <italic>fosA</italic>, <italic>sul1</italic>, <italic>aadA2b</italic>, <italic>irp1</italic>, <italic>irp2</italic><break/>No. of SNPs: NA</td>
<td align="left" valign="top">112,364&#x2009;bp, nonconjugative, <italic>bla</italic><sub>KPC-14</sub>, <italic>bla</italic><sub>TEM-1</sub>, <italic>fosA3</italic>, <italic>rmtB</italic><break/>No. of SNPs: NA</td>
<td align="left" valign="top">101,767&#x2009;bp, conjugative, <italic>tet</italic>(A), <italic>catA2</italic>, <italic>bla</italic><sub>LAP-2</sub>, <italic>qnrS1</italic>, <italic>sul2</italic>, <italic>bla</italic><sub>KPC-14</sub>, <italic>bla</italic><sub>SHV-12</sub><break/>No. of SNPs: NA</td>
<td align="left" valign="top">204,770&#x2009;bp, <italic>rmpA2</italic>, <italic>iutA</italic>, <italic>iucABCD</italic><break/>No. of SNPs: NA</td>
</tr>
<tr>
<td align="left" valign="top"><italic>K. pneumoniae</italic> SP1030</td>
<td align="left" valign="top">Patient B</td>
<td align="left" valign="top">5,477,323&#x2009;bp,<break/><italic>bla</italic><sub>SHV-11</sub>, <italic>fosA</italic>, <italic>sul1</italic>, <italic>aadA2b</italic>, <italic>irp1</italic>, <italic>irp2</italic><break/>No. of SNPs: 4</td>
<td align="left" valign="top">112,363&#x2009;bp, nonconjugative, <italic>bla</italic><sub>KPC-14</sub>, <italic>bla</italic><sub>TEM-1</sub>, <italic>fosA3</italic>, <italic>rmtB</italic><break/>No. of SNPs: 1</td>
<td align="left" valign="top">101,768&#x2009;bp, conjugative, <italic>tet</italic>(A), <italic>catA2</italic>, <italic>bla</italic><sub>LAP-2</sub>, <italic>qnrS1</italic>, <italic>sul2</italic>, <italic>bla</italic><sub>KPC-14</sub>, <italic>bla</italic><sub>SHV-12</sub><break/>No. of SNPs: 1</td>
<td align="left" valign="top">204,770&#x2009;bp, <italic>rmpA2</italic>, <italic>iutA</italic>, <italic>iucABCD</italic><break/>No. of SNPs: 0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn3">
<label>a</label>
<p>The SNP numbers was estimated by Snippy with the reference sequences of <italic>K. pneumoniae</italic> F1025.</p>
</fn>
<p>No., numbers; NA, not applicable.</p>
</table-wrap-foot>
</table-wrap>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Comparisons of <italic>bla</italic><sub>KPC</sub>-carrying plasmid <bold>(A)</bold>, <italic>tet</italic>(A)-carrying plasmid <bold>(B)</bold>, and the virulence plasmid <bold>(C)</bold> with the reference plasmids. The circles from inside to outside display the scale in kilobase pairs, the GC skew, the GC content, the similarity to the reference plasmids, and the annotation of the plasmid in our study, respectively. All insertion sequences are labeled orange, antimicrobial resistance genes are labeled red, genes encoding proteins with known functions are labeled blue, <italic>rep</italic> genes are labeled green, and the hypothetical proteins are labeled gray.</p>
</caption>
<graphic xlink:href="fmicb-14-1261261-g002.tif"/>
</fig>
<p>The type 1 Tet(A) variant colocalized with the <italic>catA2</italic>, <italic>bla</italic><sub>LAP-2</sub>, <italic>qnrS1</italic>, and <italic>sul2</italic> genes on unknown Inc-type plasmids with sizes of 84,754&#x2009;bp, 101,767&#x2009;bp, and 101,768&#x2009;bp for <italic>K. pneumoniae</italic> SP1023, F1025, and SP1030, respectively (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). This backbone was also observed in <italic>tet</italic>(A)-harboring plasmids in <italic>K. pneumoniae</italic> C76 and <italic>K. pneumoniae</italic> CT77 with 100% identity (91% coverage) but integrated with a 4,956&#x2009;bp DNA fragment (based on <italic>K. pneumoniae</italic> SP1030) containing the <italic>bla</italic><sub>LAP-2</sub> and <italic>qnrS1</italic> genes. Unlike plasmid pSP1023-tetA in <italic>K. pneumoniae</italic> SP1023, the <italic>bla</italic><sub>KPC-14</sub> locus of 8,248&#x2009;bp was inserted into the <italic>tet</italic>(A)-carrying plasmids in <italic>K. pneumoniae</italic> F1025 and SP1030, which were further designated as plasmid pF1025-KPC-tetA and pSP1030-KPC-tetA, respectively. Another resistance locus harboring the <italic>bla</italic><sub>SHV-12</sub> gene was also observed in these two plasmids but was absent in plasmid pSP1023-tetA. The structural discrepancy in these <italic>tet</italic>(A)-carrying plasmids echoed the differences in the genetic and phenotypic profiles of the transconjugants we noticed. These observations indicated that the plasmids carrying both <italic>tet</italic>(A) and <italic>bla</italic><sub>KPC-14</sub> genes possibly evolved from those with a single occurrence of the <italic>tet</italic>(A) gene, such as pSP1023-tetA, which could also be further traced back to previously identified plasmids. The <italic>bla</italic><sub>KPC-14</sub> genes were flanked by an NTE<sub>KPC</sub>-Ib-like transposon similar to that on the IncFII/IncR plasmids in our study, indicating that these nonconjugative plasmids might be the source of the <italic>bla</italic><sub>KPC-14</sub>-carrying fragments for plasmids pF1025-KPC-tetA and pSP1030-KPC-tetA. As previously reported, the diversity of mobile elements and transposons in NTE<sub>KPC</sub>-I elements actively promoted the transposition of the <italic>bla</italic><sub>KPC</sub> genes to various genetic locations (<xref ref-type="bibr" rid="ref38">Yang et al., 2021</xref>); thus, we speculated that the mobilization event mediated the integration of the <italic>bla</italic><sub>KPC-14</sub> locus into the backbones of <italic>tet</italic>(A)-carrying plasmids, thus creating the binary carriage profile of <italic>bla</italic><sub>KPC-14</sub>-harboring plasmids in <italic>K. pneumoniae</italic> F1025 and SP1030. The integrated plasmids retained the fully functional conjugative genes homologous to the previous <italic>tet</italic>(A)-carrying plasmids (<xref ref-type="fig" rid="fig2">Figure 2</xref>), further facilitating the cotransfer and dissemination of KPC-14 and the type 1 Tet(A) variant among <italic>Enterobacterales</italic>.</p>
</sec>
<sec id="sec14">
<label>3.5.</label>
<title>Virulence analysis</title>
<p>The hypervirulent phenotype of three CRKP was observed in the <italic>G. mellonella</italic> infection model (<xref ref-type="fig" rid="fig3">Figure 3</xref>). At 48&#x2009;h post-infection, the survival rates of larvae infected by strains SP1023, F1025, and SP1030 were 12.5, 29.2, and 16.7%, respectively, which were lower than that of larvae infected by the negative control strain <italic>K. pneumoniae</italic> FJ8 at 79.2%. WGS analysis showed that these strains expressed the same virulence factor profile specific to hypervirulent <italic>K. pneumoniae</italic> (hvKP), including RmpA2, aerobactin, and yersiniabactin (<xref ref-type="table" rid="tab2">Table 2</xref>); thus, the CRKP in our study were classified as CR-hvKP. Long-read sequencing revealed that the <italic>rmpA2</italic> and the <italic>iutAiucABCD</italic> gene cluster (aerobactin siderophore) were located on the IncHI1B/IncFIB-type pLVPK-like plasmid with sizes ranging from 204,770 to 204,778&#x2009;bp (<xref ref-type="table" rid="tab3">Table 3</xref>, <xref ref-type="fig" rid="fig2">Figure 2C</xref>). These plasmids showed high identity (&#x003E;99%) to a variety of other hypervirulence plasmids of <italic>K. pneumoniae</italic> in the NCBI database, indicating the wide dissemination of these plasmids conferring hypervirulent phenotypes.</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Virulence potential of <italic>K. pneumoniae</italic> strains in a <italic>G. mellonella</italic> infection model.</p>
</caption>
<graphic xlink:href="fmicb-14-1261261-g003.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="sec15">
<label>4.</label>
<title>Discussion</title>
<p>The rapid and wide dissemination of KPC-producing CRKP represents a serious threat to public health and a serious challenge for healthcare workers. Most of the KPC-producing CRKP also harbor determinants that confer resistance to a variety of antimicrobial agents thus further limiting the clinical options for treatment. CZA exhibited great activity against these multidrug-resistant pathogens; however, many concerns have been raised over the emergence of resistant KPC variants with various genetic landscapes, demonstrating the substantial evolutionary potential of this enzyme (<xref ref-type="bibr" rid="ref16">Findlay et al., 2021</xref>; <xref ref-type="bibr" rid="ref25">Liu et al., 2022b</xref>; <xref ref-type="bibr" rid="ref37">Wu et al., 2022</xref>).</p>
<p>In this study, we described the emergence of the CZA-resistant CRKP harbored the <italic>bla</italic><sub>KPC-14</sub> gene on two structurally different plasmids. Three CRKP collectively harbored a <italic>bla</italic><sub>KPC-14</sub>-carrying IncFII/IncR plasmid, which was widespread and commonly identified in KPC-producing CRKP in China (<xref ref-type="bibr" rid="ref7">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="ref14">Dong et al., 2018</xref>). There were a few studies that described the emergence and <italic>in vivo</italic> selection of KPC-14 rendering resistance following CZA treatment (<xref ref-type="bibr" rid="ref4">Bianco et al., 2020</xref>; <xref ref-type="bibr" rid="ref29">Niu et al., 2020</xref>). However, due to the absence of CZA therapeutic regimens during the hospitalization of the two patients, the source of the <italic>bla</italic><sub>KPC-14</sub> gene in our hospital was still unclear. As recently shown, the KPC-14 enzyme demonstrated the loss of carbapenemase activity (<xref ref-type="bibr" rid="ref12">Compain and Arthur, 2017</xref>), which was true for the low-level resistance or susceptibility to the carbapenems of KPC-14 producers in our study. This finding reminded us that these resistance determinants may silently spread and be easily ignored during routine surveillance in clinical settings. Although these <italic>bla</italic><sub>KPC-14</sub>-encoding plasmids were nonconjugative, they could provide translocatable fragments as reservoirs for the mobilization of the <italic>bla</italic><sub>KPC-14</sub> gene into other plasmid backbones. In this study, we also identified a conjugative plasmid integrated with the <italic>bla</italic><sub>KPC-14</sub>-containing NTE<sub>KPC</sub>-I element, which was relatively prevalent among clinical strains in China (<xref ref-type="bibr" rid="ref6">Cerdeira et al., 2019</xref>). Structurally similar plasmids were previously reported in our hospital with the colocation of the type 1 Tet(A) variant (<xref ref-type="bibr" rid="ref8">Chen et al., 2021</xref>), which was associated with resistance to another clinically important antibiotic, tigecycline. Moreover, the evolution of these plasmids was observed, as they could additionally capture various other resistance loci, further contributing to the coselection and persistence of these determinants of resistance to last-line antibiotics. The considerable genetic plasticity of these plasmids enabled the acquisition of further resistance-encoding and hypervirulence-encoding genetic elements; thus, these isolates can better adapt to various environments to stimulate the spread of <italic>bla</italic><sub>KPC-14</sub> among <italic>Enterobacterales</italic>.</p>
<p>The multidimensional transmission and potential silent spread of <italic>bla</italic><sub>KPC-14</sub> in CRKP is concerning, especially in those that also carry hypervirulent phenotypes. The KPC-14-producing CRKP in our study originated from the same ST11 clone, which was the dominant clone of CRKP in China and served as a salient example of the evolutionary acquisition of resistance genes and virulence factors for a newly emerged superbug (<xref ref-type="bibr" rid="ref22">Liao et al., 2020</xref>). The pLVPK-like virulence plasmids commonly converted normal ST11 strains to ST11 hvKP and were first reported in our hospital in 2018 (<xref ref-type="bibr" rid="ref17">Gu et al., 2018</xref>). These plasmids enhanced the environmental survival and the rapid dissemination of the hypervirulent phenotype with a limited fitness cost in ST11 CRKP (<xref ref-type="bibr" rid="ref39">Zhou et al., 2020</xref>), consistent with the persistence of these plasmids during spread and evolution observed in our study. More worrisome, these superbugs still have the exceptional ability to attain extra resistance to clinically important drugs such as colistin and tigecycline via <italic>in vivo</italic> selection following antibiotic treatment. This could have affected <italic>K. pneumoniae</italic> F1025 in our study, which displayed resistance to almost all antibiotics, including CZA, colistin, and tigecycline. The emergence of such XDR strains may cause severe infections that are difficult to treat with current antibiotics, especially for ICU patients with complicated diseases.</p>
</sec>
<sec sec-type="conclusions" id="sec16">
<label>5.</label>
<title>Conclusion</title>
<p>In this study, we described the evolution of a conjugative mosaic plasmid encoding the <italic>bla</italic><sub>KPC-14</sub> gene via mobile elements in CR-hvKP. The nonconjugative IncFII/IncR plasmid could serve as the reservoir of the mobilizable fragment of the <italic>bla</italic><sub>KPC-14</sub> gene, similar to NTE<sub>KPC</sub>-I elements, allowing it to integrate into other conjugative plasmid backbones, further facilitating the spread of <italic>bla</italic><sub>KPC-14</sub>. Therefore, constant surveillance to control the development and further spread of CZA resistance is of great significance.</p>
</sec>
<sec sec-type="data-availability" id="sec17">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.</p>
</sec>
<sec sec-type="ethics-statement" id="sec18">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Ethics Committee of The Second Affiliated Hospital of Zhejiang University School of Medicine. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from primarily isolated as part of your previous study for which ethical approval was obtained. Written informed consent for participation was not required from the participants or the participants&#x2019; legal guardians/next of kin in accordance with the national legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="sec19">
<title>Author contributions</title>
<p>LW: Data curation, Formal analysis, Investigation, Methodology, Resources, Validation, Writing &#x2013; original draft. WS: Data curation, Formal analysis, Investigation, Validation, Writing &#x2013; original draft, Software, Visualization. JC: Conceptualization, Funding acquisition, Project administration, Supervision, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec20">
<title>Funding</title>
<p>The work was supported by the Zhejiang Provincial Natural Science Foundation of China (LY22H200001).</p>
</sec>
<sec sec-type="COI-statement" id="sec21">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<fn-group>
<fn id="fn0001">
<p><sup>1</sup>
<ext-link xlink:href="http://www.chinets.com/" ext-link-type="uri">http://www.chinets.com/</ext-link>
</p>
</fn>
<fn id="fn0002">
<p><sup>2</sup>
<ext-link xlink:href="https://www.fda.gov/drugs/developmentresources/tigecycline-injection-products" ext-link-type="uri">https://www.fda.gov/drugs/developmentresources/tigecycline-injection-products</ext-link>
</p>
</fn>
<fn id="fn0003">
<p><sup>3</sup>
<ext-link xlink:href="https://www.genomicepidemiology.org/" ext-link-type="uri">https://www.genomicepidemiology.org/</ext-link>
</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="ref1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alikhan</surname> <given-names>N.-F.</given-names></name> <name><surname>Petty</surname> <given-names>N. K.</given-names></name> <name><surname>Ben Zakour</surname> <given-names>N. L.</given-names></name> <name><surname>Beatson</surname> <given-names>S. A.</given-names></name></person-group> (<year>2011</year>). <article-title>BLAST ring image generator (BRIG): simple prokaryote genome comparisons</article-title>. <source>BMC Genomics</source> <volume>12</volume>:<fpage>402</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2164-12-402</pub-id>, PMID: <pub-id pub-id-type="pmid">21824423</pub-id></citation></ref>
<ref id="ref2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname> <given-names>M. D.</given-names></name> <name><surname>Winkler</surname> <given-names>M. L.</given-names></name> <name><surname>Taracila</surname> <given-names>M. A.</given-names></name> <name><surname>Page</surname> <given-names>M. G.</given-names></name> <name><surname>Desarbre</surname> <given-names>E.</given-names></name> <name><surname>Kreiswirth</surname> <given-names>B. N.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title><italic>Klebsiella pneumoniae</italic> Carbapenemase-2 (KPC-2), substitutions at ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from &#x03B2;-lactamase protein engineering</article-title>. <source>mBio</source> <volume>8</volume>, <fpage>e00528</fpage>&#x2013;<lpage>e00517</lpage>. doi: <pub-id pub-id-type="doi">10.1128/mBio.00528-17</pub-id></citation></ref>
<ref id="ref3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bianco</surname> <given-names>G.</given-names></name> <name><surname>Boattini</surname> <given-names>M.</given-names></name> <name><surname>Iannaccone</surname> <given-names>M.</given-names></name> <name><surname>Bondi</surname> <given-names>A.</given-names></name> <name><surname>Ghibaudo</surname> <given-names>D.</given-names></name> <name><surname>Zanotto</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Carbapenemase detection testing in the era of ceftazidime/avibactam-resistant KPC-producing <italic>Enterobacterales</italic>: a 2-year experience</article-title>. <source>J. Glob. Antimicrob. Resist.</source> <volume>24</volume>, <fpage>411</fpage>&#x2013;<lpage>414</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jgar.2021.02.008</pub-id></citation></ref>
<ref id="ref4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bianco</surname> <given-names>G.</given-names></name> <name><surname>Boattini</surname> <given-names>M.</given-names></name> <name><surname>Iannaccone</surname> <given-names>M.</given-names></name> <name><surname>Cavallo</surname> <given-names>R.</given-names></name> <name><surname>Costa</surname> <given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Bloodstream infection by two subpopulations of <italic>Klebsiella pneumoniae</italic> ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay</article-title>. <source>J. Antimicrob. Chemother.</source> <volume>75</volume>, <fpage>3075</fpage>&#x2013;<lpage>3076</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkaa283</pub-id>, PMID: <pub-id pub-id-type="pmid">32676660</pub-id></citation></ref>
<ref id="ref5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname> <given-names>J. C.</given-names></name> <name><surname>Zhou</surname> <given-names>H. W.</given-names></name> <name><surname>Zhang</surname> <given-names>R.</given-names></name> <name><surname>Chen</surname> <given-names>G.-X.</given-names></name></person-group> (<year>2008</year>). <article-title>Emergence of <italic>Serratia marcescens</italic>, <italic>Klebsiella pneumoniae</italic>, and <italic>Escherichia coli</italic> isolates possessing the plasmid-mediated carbapenem-hydrolyzing &#x03B2;-lactamase KPC-2 in intensive care units of a Chinese hospital</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>52</volume>, <fpage>2014</fpage>&#x2013;<lpage>2018</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01539-07</pub-id>, PMID: <pub-id pub-id-type="pmid">18332176</pub-id></citation></ref>
<ref id="ref6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cerdeira</surname> <given-names>L. T.</given-names></name> <name><surname>Lam</surname> <given-names>M. M. C.</given-names></name> <name><surname>Wyres</surname> <given-names>K. L.</given-names></name> <name><surname>Wick</surname> <given-names>R. R.</given-names></name> <name><surname>Judd</surname> <given-names>L. M.</given-names></name> <name><surname>Lopes</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Small IncQ1 and col-like plasmids harboring <italic>bla</italic><sub>KPC-2</sub> and non-Tn <italic>4401</italic> elements (NTE<sub>KPC</sub>-IId) in high-risk lineages of <italic>Klebsiella pneumoniae</italic> CG258</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>63</volume>, <fpage>e02140</fpage>&#x2013;<lpage>e02118</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.02140-18</pub-id>, PMID: <pub-id pub-id-type="pmid">30602517</pub-id></citation></ref>
<ref id="ref7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>L.</given-names></name> <name><surname>Mathema</surname> <given-names>B.</given-names></name> <name><surname>Chavda</surname> <given-names>K. D.</given-names></name> <name><surname>DeLeo</surname> <given-names>F. R.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <name><surname>Kreiswirth</surname> <given-names>B. N.</given-names></name></person-group> (<year>2014</year>). <article-title>Carbapenemase-producing <italic>Klebsiella pneumoniae</italic>: molecular and genetic decoding</article-title>. <source>Trends Microbiol.</source> <volume>22</volume>, <fpage>686</fpage>&#x2013;<lpage>696</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tim.2014.09.003</pub-id>, PMID: <pub-id pub-id-type="pmid">25304194</pub-id></citation></ref>
<ref id="ref8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>J.</given-names></name> <name><surname>Zeng</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>R.</given-names></name> <name><surname>Cai</surname> <given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title><italic>In vivo</italic> emergence of colistin and tigecycline resistance in carbapenem-resistant hypervirulent <italic>Klebsiella pneumoniae</italic> during antibiotics treatment</article-title>. <source>Front. Microbiol.</source> <volume>12</volume>:<fpage>702956</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2021.702956</pub-id>, PMID: <pub-id pub-id-type="pmid">34603229</pub-id></citation></ref>
<ref id="ref9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname> <given-names>S.-K.</given-names></name> <name><surname>Huang</surname> <given-names>L.-Y.</given-names></name> <name><surname>Chen</surname> <given-names>H.</given-names></name> <name><surname>Tsai</surname> <given-names>Y.-K.</given-names></name> <name><surname>Liou</surname> <given-names>C.-H.</given-names></name> <name><surname>Lin</surname> <given-names>J.-C.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Roles of <italic>ramR</italic> and <italic>tet</italic>(a) mutations in conferring tigecycline resistance in carbapenem-resistant <italic>Klebsiella pneumoniae</italic> clinical isolates</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>61</volume>, <fpage>e00391</fpage>&#x2013;<lpage>e00317</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00391-17</pub-id>, PMID: <pub-id pub-id-type="pmid">28533243</pub-id></citation></ref>
<ref id="ref10"><citation citation-type="book"><person-group person-group-type="author"><collab id="coll1">Clinical and Laboratory Standards Institute</collab></person-group> (<year>2018</year>). <source>Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically</source>, <edition>11</edition>. <publisher-loc>Wayne, PA</publisher-loc>: <publisher-name>CLSI standard M07</publisher-name>.</citation></ref>
<ref id="ref11"><citation citation-type="book"><person-group person-group-type="author"><collab id="coll2">Clinical and Laboratory Standards Institute</collab></person-group> (<year>2021</year>). <source>Performance standards for antimicrobial susceptibility Ttesting</source>, <edition>31</edition>. <publisher-loc>Wayne, PA</publisher-loc>: <publisher-name>CLSI supplement M100</publisher-name>.</citation></ref>
<ref id="ref12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Compain</surname> <given-names>F.</given-names></name> <name><surname>Arthur</surname> <given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 &#x03B2;-lactamase</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>61</volume>, <fpage>e00451</fpage>&#x2013;<lpage>e00417</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00451-17</pub-id></citation></ref>
<ref id="ref13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Criscuolo</surname> <given-names>M.</given-names></name> <name><surname>Trecarichi</surname> <given-names>E. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Ceftazidime/avibactam and ceftolozane/tazobactam for multidrug-resistant gram hegatives in patients with hematological malignancies: current experiences</article-title>. <source>Antibiotics</source> <volume>9</volume>:<fpage>58</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics9020058</pub-id>, PMID: <pub-id pub-id-type="pmid">32028615</pub-id></citation></ref>
<ref id="ref14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>N.</given-names></name> <name><surname>Yang</surname> <given-names>X.</given-names></name> <name><surname>Zhang</surname> <given-names>R.</given-names></name> <name><surname>Chan</surname> <given-names>E. W.-C.</given-names></name> <name><surname>Chen</surname> <given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Tracking microevolution events among ST11 carbapenemase-producing hypervirulent <italic>Klebsiella pneumoniae</italic> outbreak strains</article-title>. <source>Emerg. Microbes Infect.</source> <volume>7</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41426-018-0146-6</pub-id></citation></ref>
<ref id="ref15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Kady</surname> <given-names>R. A. E.-H.</given-names></name> <name><surname>Elbaiomy</surname> <given-names>M. A.</given-names></name> <name><surname>Elnagar</surname> <given-names>R. M.</given-names></name></person-group> (<year>2022</year>). <article-title>Molecular mechanisms mediating ceftazidime/avibactam resistance amongst carbapenem-resistant <italic>Klebsiella pneumoniae</italic> isolates from cancer patients</article-title>. <source>Infect. Drug Resist.</source> <volume>15</volume>, <fpage>5929</fpage>&#x2013;<lpage>5940</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S384972</pub-id>, PMID: <pub-id pub-id-type="pmid">36247738</pub-id></citation></ref>
<ref id="ref16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Findlay</surname> <given-names>J.</given-names></name> <name><surname>Poirel</surname> <given-names>L.</given-names></name> <name><surname>Juhas</surname> <given-names>M.</given-names></name> <name><surname>Nordmann</surname> <given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>KPC-mediated resistance to ceftazidime-avibactam and collateral effects in <italic>Klebsiella pneumoniae</italic></article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>65</volume>:<fpage>e0089021</fpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00890-21</pub-id>, PMID: <pub-id pub-id-type="pmid">34228551</pub-id></citation></ref>
<ref id="ref17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>D.</given-names></name> <name><surname>Dong</surname> <given-names>N.</given-names></name> <name><surname>Zheng</surname> <given-names>Z.</given-names></name> <name><surname>Lin</surname> <given-names>D.</given-names></name> <name><surname>Huang</surname> <given-names>M.</given-names></name> <name><surname>Wang</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>A fatal outbreak of ST11 carbapenem-resistant hypervirulent <italic>Klebsiella pneumoniae</italic> in a Chinese hospital: a molecular epidemiological study</article-title>. <source>Lancet Infect. Dis.</source> <volume>18</volume>, <fpage>37</fpage>&#x2013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30489-9</pub-id></citation></ref>
<ref id="ref18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Humphries</surname> <given-names>R. M.</given-names></name> <name><surname>Hemarajata</surname> <given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Resistance to ceftazidime-avibactam in <italic>Klebsiella pneumoniae</italic> due to porin mutations and the increased expression of KPC-3</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>61</volume>, <fpage>e00537</fpage>&#x2013;<lpage>e00517</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00537-17</pub-id>, PMID: <pub-id pub-id-type="pmid">28396547</pub-id></citation></ref>
<ref id="ref19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>M.</given-names></name> <name><surname>Sun</surname> <given-names>B.</given-names></name> <name><surname>Huang</surname> <given-names>Y.</given-names></name> <name><surname>Liu</surname> <given-names>C.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Ren</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Diversity of ceftazidime-avibactam resistance mechanism in KPC-2-producing <italic>Klebsiella pneumoniae</italic> under antibiotic selection pressure</article-title>. <source>Infect. Drug Resist.</source> <volume>15</volume>, <fpage>4627</fpage>&#x2013;<lpage>4636</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S371285</pub-id>, PMID: <pub-id pub-id-type="pmid">36003991</pub-id></citation></ref>
<ref id="ref20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kolmogorov</surname> <given-names>M.</given-names></name> <name><surname>Bickhart</surname> <given-names>D. M.</given-names></name> <name><surname>Behsaz</surname> <given-names>B.</given-names></name> <name><surname>Gurevich</surname> <given-names>A.</given-names></name> <name><surname>Rayko</surname> <given-names>M.</given-names></name> <name><surname>Shin</surname> <given-names>S. B.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>metaFlye: scalable long-read metagenome assembly using repeat graphs</article-title>. <source>Nat. Methods</source> <volume>17</volume>, <fpage>1103</fpage>&#x2013;<lpage>1110</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41592-020-00971-x</pub-id>, PMID: <pub-id pub-id-type="pmid">33020656</pub-id></citation></ref>
<ref id="ref21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname> <given-names>M. M. C.</given-names></name> <name><surname>Wick</surname> <given-names>R. R.</given-names></name> <name><surname>Watts</surname> <given-names>S. C.</given-names></name> <name><surname>Cerdeira</surname> <given-names>L. T.</given-names></name> <name><surname>Wyres</surname> <given-names>K. L.</given-names></name> <name><surname>Holt</surname> <given-names>K. E.</given-names></name></person-group> (<year>2021</year>). <article-title>A genomic surveillance framework and genotyping tool for <italic>Klebsiella pneumoniae</italic> and its related species complex</article-title>. <source>Nat. Commun.</source> <volume>12</volume>:<fpage>4188</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-021-24448-3</pub-id>, PMID: <pub-id pub-id-type="pmid">34234121</pub-id></citation></ref>
<ref id="ref22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>W.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>W.</given-names></name></person-group> (<year>2020</year>). <article-title>Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant <italic>Klebsiella pneumoniae</italic> in China: a review over the last 10 years</article-title>. <source>J. Glob. Antimicrob. Resist.</source> <volume>23</volume>, <fpage>174</fpage>&#x2013;<lpage>180</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jgar.2020.09.004</pub-id></citation></ref>
<ref id="ref23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linh</surname> <given-names>T. D.</given-names></name> <name><surname>Thu</surname> <given-names>N. H.</given-names></name> <name><surname>Shibayama</surname> <given-names>K.</given-names></name> <name><surname>Suzuki</surname> <given-names>M.</given-names></name> <name><surname>Yoshida</surname> <given-names>L.</given-names></name> <name><surname>Thai</surname> <given-names>P. D.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Expansion of KPC-producing <italic>Enterobacterales</italic> in four large hospitals in Hanoi, Vietnam</article-title>. <source>J. Glob. Antimicrob. Resist.</source> <volume>27</volume>, <fpage>200</fpage>&#x2013;<lpage>211</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jgar.2021.09.007</pub-id></citation></ref>
<ref id="ref24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>C.</given-names></name> <name><surname>Dong</surname> <given-names>N.</given-names></name> <name><surname>Chan</surname> <given-names>E. W. C.</given-names></name> <name><surname>Chen</surname> <given-names>S.</given-names></name> <name><surname>Zhang</surname> <given-names>R.</given-names></name></person-group> (<year>2022a</year>). <article-title>Molecular epidemiology of carbapenem-resistant <italic>Klebsiella pneumoniae</italic> in China, 2016&#x2013;20</article-title>. <source>Lancet Infect. Dis.</source> <volume>22</volume>, <fpage>167</fpage>&#x2013;<lpage>168</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(22)00009-3</pub-id>, PMID: <pub-id pub-id-type="pmid">35092791</pub-id></citation></ref>
<ref id="ref25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>C.</given-names></name> <name><surname>Wu</surname> <given-names>Y.</given-names></name> <name><surname>Huang</surname> <given-names>L.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Sun</surname> <given-names>Q.</given-names></name> <name><surname>Lu</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2022b</year>). <article-title>The rapid emergence of ceftazidime-avibactam resistance mediated by KPC variants in carbapenem-resistant <italic>Klebsiella pneumoniae</italic> in Zhejiang province, China</article-title>. <source>Antibiotics</source> <volume>11</volume>:<fpage>731</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics11060731</pub-id>, PMID: <pub-id pub-id-type="pmid">35740138</pub-id></citation></ref>
<ref id="ref26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Livermore</surname> <given-names>D. M.</given-names></name> <name><surname>Warner</surname> <given-names>M.</given-names></name> <name><surname>Jamrozy</surname> <given-names>D.</given-names></name> <name><surname>Mushtaq</surname> <given-names>S.</given-names></name> <name><surname>Nichols</surname> <given-names>W. W.</given-names></name> <name><surname>Mustafa</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title><italic>In vitro</italic> selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>59</volume>, <fpage>5324</fpage>&#x2013;<lpage>5330</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00678-15</pub-id></citation></ref>
<ref id="ref27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magiorakos</surname> <given-names>A.-P.</given-names></name> <name><surname>Srinivasan</surname> <given-names>A.</given-names></name> <name><surname>Carey</surname> <given-names>R. B.</given-names></name> <name><surname>Carmeli</surname> <given-names>Y.</given-names></name> <name><surname>Falagas</surname> <given-names>M. E.</given-names></name> <name><surname>Giske</surname> <given-names>C. G.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance</article-title>. <source>Clin. Microbiol. Infect.</source> <volume>18</volume>, <fpage>268</fpage>&#x2013;<lpage>281</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03570.x</pub-id>, PMID: <pub-id pub-id-type="pmid">21793988</pub-id></citation></ref>
<ref id="ref28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname> <given-names>M. M.</given-names></name> <name><surname>Advincula</surname> <given-names>M. R.</given-names></name> <name><surname>Malczynski</surname> <given-names>M.</given-names></name> <name><surname>Barajas</surname> <given-names>G.</given-names></name> <name><surname>Qi</surname> <given-names>C.</given-names></name> <name><surname>Scheetz</surname> <given-names>M. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Quantifying the clinical virulence of <italic>Klebsiella pneumoniae</italic> producing carbapenemase <italic>Klebsiella pneumoniae</italic> with a <italic>galleria mellonellamodel</italic> and a pilot study to translate to patient outcomes</article-title>. <source>BMC Infect. Dis.</source> <volume>14</volume>:<fpage>31</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2334-14-31</pub-id>, PMID: <pub-id pub-id-type="pmid">24428847</pub-id></citation></ref>
<ref id="ref29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname> <given-names>S.</given-names></name> <name><surname>Chavda</surname> <given-names>K. D.</given-names></name> <name><surname>Wei</surname> <given-names>J.</given-names></name> <name><surname>Zou</surname> <given-names>C.</given-names></name> <name><surname>Marshall</surname> <given-names>S. H.</given-names></name> <name><surname>Dhawan</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>A ceftazidime-avibactam-resistant and carbapenem-susceptible <italic>Klebsiella pneumoniae</italic> strain harboring <italic>bla</italic><sub>KPC-14</sub> isolated in New York City</article-title>. <source>mSphere</source> <volume>5</volume>, <fpage>e00775</fpage>&#x2013;<lpage>e00720</lpage>. doi: <pub-id pub-id-type="doi">10.1128/mSphere.00775-20</pub-id></citation></ref>
<ref id="ref30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Overbeek</surname> <given-names>R.</given-names></name> <name><surname>Olson</surname> <given-names>R.</given-names></name> <name><surname>Pusch</surname> <given-names>G. D.</given-names></name> <name><surname>Olsen</surname> <given-names>G. J.</given-names></name> <name><surname>Davis</surname> <given-names>J. J.</given-names></name> <name><surname>Disz</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>The SEED and the rapid annotation of microbial genomes using subsystems technology (RAST)</article-title>. <source>Nucleic Acids Res.</source> <volume>42</volume>, <fpage>D206</fpage>&#x2013;<lpage>D214</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkt1226</pub-id>, PMID: <pub-id pub-id-type="pmid">24293654</pub-id></citation></ref>
<ref id="ref31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>P&#x00E9;rez-Galera</surname> <given-names>S.</given-names></name> <name><surname>Bravo-Ferrer</surname> <given-names>J. M.</given-names></name> <name><surname>Paniagua</surname> <given-names>M.</given-names></name> <name><surname>Kostyanev</surname> <given-names>T.</given-names></name> <name><surname>De Kraker</surname> <given-names>M. E. A.</given-names></name> <name><surname>Feifel</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Risk factors for infections caused by carbapenem-resistant <italic>Enterobacterales</italic>: an international matched case-control-control study (EURECA)</article-title>. <source>eClinicalMedicine</source> <volume>57</volume>:<fpage>101871</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2023.101871</pub-id>, PMID: <pub-id pub-id-type="pmid">36895801</pub-id></citation></ref>
<ref id="ref32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>Q.</given-names></name> <name><surname>Wen</surname> <given-names>L.</given-names></name> <name><surname>Chen</surname> <given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Combined effect of polymyxin B and tigecycline to overcome heteroresistance in carbapenem-resistant <italic>Klebsiella pneumoniae</italic></article-title>. <source>Microbiol. Spectr.</source> <volume>9</volume>, <fpage>e00152</fpage>&#x2013;<lpage>e00121</lpage>. doi: <pub-id pub-id-type="doi">10.1128/Spectrum.00152-21</pub-id>, PMID: <pub-id pub-id-type="pmid">34704782</pub-id></citation></ref>
<ref id="ref33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Duin</surname> <given-names>D.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation &#x03B2;-lactam/&#x03B2;-lactamase inhibitor combinations</article-title>. <source>Clin. Infect. Dis.</source> <volume>63</volume>, <fpage>234</fpage>&#x2013;<lpage>241</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciw243</pub-id>, PMID: <pub-id pub-id-type="pmid">27098166</pub-id></citation></ref>
<ref id="ref34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname> <given-names>B. J.</given-names></name> <name><surname>Abeel</surname> <given-names>T.</given-names></name> <name><surname>Shea</surname> <given-names>T.</given-names></name> <name><surname>Priest</surname> <given-names>M.</given-names></name> <name><surname>Abouelliel</surname> <given-names>A.</given-names></name> <name><surname>Sakthikumar</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement</article-title>. <source>PLoS One</source> <volume>9</volume>:<fpage>e112963</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0112963</pub-id></citation></ref>
<ref id="ref35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>M.</given-names></name> <name><surname>Earley</surname> <given-names>M.</given-names></name> <name><surname>Chen</surname> <given-names>L.</given-names></name> <name><surname>Hanson</surname> <given-names>B. M.</given-names></name> <name><surname>Yu</surname> <given-names>Y.</given-names></name> <name><surname>Liu</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Clinical outcomes and bacterial characteristics of carbapenem-resistant <italic>Klebsiella pneumoniae</italic> complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study</article-title>. <source>Lancet Infect. Dis.</source> <volume>22</volume>, <fpage>401</fpage>&#x2013;<lpage>412</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(21)00399-6</pub-id>, PMID: <pub-id pub-id-type="pmid">34767753</pub-id></citation></ref>
<ref id="ref36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L.</given-names></name> <name><surname>Shen</surname> <given-names>W.</given-names></name> <name><surname>Zhang</surname> <given-names>R.</given-names></name> <name><surname>Cai</surname> <given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>Identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in <italic>Citrobacter koseri</italic> following ceftazidime-avibactam treatment</article-title>. <source>Front. Microbiol.</source> <volume>13</volume>:<fpage>930777</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2022.930777</pub-id>, PMID: <pub-id pub-id-type="pmid">35794918</pub-id></citation></ref>
<ref id="ref37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>Y.</given-names></name> <name><surname>Yang</surname> <given-names>X.</given-names></name> <name><surname>Liu</surname> <given-names>C.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Cheung</surname> <given-names>Y. C.</given-names></name> <name><surname>Chan</surname> <given-names>W. C.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Identification of a KPC variant conferring resistance to ceftazidime-avibactam from ST11 carbapenem-resistant <italic>Klebsiella pneumoniae</italic> strains</article-title>. <source>Microbiol. Spectr.</source> <volume>10</volume>, <fpage>e02655</fpage>&#x2013;<lpage>e02621</lpage>. doi: <pub-id pub-id-type="doi">10.1128/spectrum.02655-21</pub-id>, PMID: <pub-id pub-id-type="pmid">35416703</pub-id></citation></ref>
<ref id="ref38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>X.</given-names></name> <name><surname>Dong</surname> <given-names>N.</given-names></name> <name><surname>Chan</surname> <given-names>E. W.-C.</given-names></name> <name><surname>Zhang</surname> <given-names>R.</given-names></name> <name><surname>Chen</surname> <given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Carbapenem resistance-encoding and virulence-encoding conjugative plasmids in <italic>Klebsiella pneumoniae</italic></article-title>. <source>Trends Microbiol.</source> <volume>29</volume>, <fpage>65</fpage>&#x2013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tim.2020.04.012</pub-id>, PMID: <pub-id pub-id-type="pmid">32448764</pub-id></citation></ref>
<ref id="ref39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>K.</given-names></name> <name><surname>Xiao</surname> <given-names>T.</given-names></name> <name><surname>David</surname> <given-names>S.</given-names></name> <name><surname>Wang</surname> <given-names>Q.</given-names></name> <name><surname>Zhou</surname> <given-names>Y.</given-names></name> <name><surname>Guo</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Novel subclone of carbapenem-resistant <italic>Klebsiella pneumoniae</italic> sequence type 11 with enhanced virulence and transmissibility</article-title>. <source>China. Emerg. Infect. Dis.</source> <volume>26</volume>, <fpage>289</fpage>&#x2013;<lpage>297</lpage>. doi: <pub-id pub-id-type="doi">10.3201/eid2602.190594</pub-id></citation></ref>
</ref-list>
</back>
</article>